Iqvia Holdings(NYSE) IQV

IQVIA Holdings Inc. helps drug makers test and sell medicines. It uses data and technology to improve patient care. These tools help companies find medical cures faster.

Data, Drugs, and Decisions

• Research & Development Solutions: Provides clinical trial services and real-world research to biopharmaceutical companies; segment revenue was $2,575 million in the three-month period ended June 30, 2026.
• Commercial Solutions: Supplies data analytics, technology, and patient engagement tools; segment revenue was $1,793 million in the three-month period ended June 30, 2026.
• Laboratory Services: Manages a global network of facilities for genomic, bioanalytical, vaccine, and biomarker analyses.
• Connected Intelligence: Combines large health data sets with artificial intelligence to provide insights to medical researchers and government agencies.

Making Strategic Moves

• Recast business segments on Jan. 1, 2026, to align with an updated operating model that merges commercial and clinical offerings.
• Borrowed $650 million on March 11, 2026, to repay maturing senior notes and support general corporate purposes.
• Issued 950 million euros of senior notes on June 11, 2026, to manage outstanding debt and revolving credit facilities.
• Increased the share repurchase authorization by $2,000 million on May 7, 2026, to expand its equity buyback program.

Global Intelligence at Scale

The company operates in over 100 countries with approximately 94,000 employees. It uses privacy-enhancing technology to analyze patient data while protecting individual identities.

The Numbers for 2026

• Revenues rose 8.7% year over year to $4,368 million in the three-month period ended June 30, 2026.
• Net cash provided by operating activities reached $1,176 million during the first six months of 2026.
• Market capitalization was $32.3 billion in the second quarter of 2026, up 19.3% year over year.
• Research & Development Solutions' contracted backlog grew to $34.2 billion as of June 30, 2026.
• The company's P/E ratio was 31.4 in the second quarter of 2026.

A New Operating Model

The company has transitioned its focus toward integrated data and clinical research solutions. Its recent reorganization reflects a shift toward more streamlined, technology-driven services for the life sciences industry.